|
1）Petersdorf S, Kopecky K, Stuart RK, et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts). 2009; 114: 790(abstr)
|
|
|
|
|
2）Burnett AK, Hills RK, Milligan D, et al. Identi-fication of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011; 29: 369-77
|
|
|
|
|
3）Burnett AK, Hills RK, Milligan D, et al. The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: Results of the UK NCRI AML16 randomized trial. Blood (ASH Annual Meeting Abstracts). 2011; 116: 582(abstr)
|
|
|
|
|
|
4）Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukae-mia(ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012; 379: 1508-16
|
|
|
|
|
|
5）Fernandez HF, Sun Z, Litzow MR, et al. Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood. 2011; 117: 5306-13
|
|
|
|
|
|
6）Lowenberg B, Beck J, Graux C, et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood. 2010; 115: 2586-91
|
|
|
|
|
|
7）Kobayashi Y, Tobinai K, Takeshita A, et al. Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study. Int J Hematol. 2009; 89(4): 460-9
|
|
|
|
|
8）Usui N, Takeshita A, Nakaseko C, et al. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study. Cancer Sci. 2011; 102: 1358-65
|
|
|
|
|